Overview

Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This study aims to assess the efficacy of peginterferon α-2b, compared to a control arm not receiving any maintenance treatment, in adult subjects with multiple myeloma who have responded to a prior induction therapy. Peginterferon α-2b will be given once weekly as an injection until disease progression or relapse, or for up to a maximum of 5 years (whichever occurs first).
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.